Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–70 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuralgia,Postherpetic Clear all
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

NCT00636636
View directory record Official record
Conditions
Neuralgia,Postherpetic
Interventions
Gabapentin Extended Release tablets, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional Results available

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

NCT01195636
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
XPF-002, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
24
States / cities
Jonesboro, Arkansas • Lomita, California • Westlake Village, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)

NCT02365636
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
TV-45070, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
77
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 4, 2026, 7:54 AM EDT
Not listed Phase 2 Interventional

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
Drug
Lead sponsor
aRigen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Beverly Hills, California • Encino, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Vaporized Marijuana on Neuropathic Pain

NCT01037088
View directory record Official record
Conditions
Neuropathic Pain, Reflex Sympathetic Dystrophy, Peripheral Neuropathy, Post-herpetic Neuralgia, Spinal Cord Injury, Multiple Sclerosis
Interventions
Mild dose cannabis, Low dose cannabis, Cannabis
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional

Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia

NCT00478179
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
Transdermal/Patch (Bupivacaine TTS [Eladur™])
Drug
Lead sponsor
Durect
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
La Jolla, California • Loma Linda, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

NCT00343733
View directory record Official record
Conditions
Pain
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
21
States / cities
Hot Springs, Arkansas • Los Gatos, California • Oxnard, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia

NCT01318226
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ATx08-001, Placebo
Drug
Lead sponsor
Aestus Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
9
States / cities
Chandler, Arizona • Peoria, Arizona • Cutler Bay (Miami), Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 4, 2026, 7:54 AM EDT
Terminated Phase 2 Interventional

[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.

NCT00354094
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Tampa, Florida • West Palm Beach, Florida • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Not applicable Interventional

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561
View directory record Official record
Conditions
Herpes Zoster, Post-herpetic Neuralgia
Interventions
Gabapentin, Valacyclovir
Drug
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 4, 2026, 7:54 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Study to Find Out if Therapy With the Drug Pregabalin Relieves Pain During Shingles Compared With Placebo

NCT00352651
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
Pregabalin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Early Phase 1 Interventional

3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)

NCT03421613
View directory record Official record
Conditions
Treatment of PHN
Interventions
3VM1001, Placebo
Drug · Other
Lead sponsor
CDA Research Group, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 3 Interventional Results available

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

NCT01270828
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
Pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
82
States / cities
Gulf Shores, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

NCT00592904
View directory record Official record
Conditions
Neuralgia
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional Results available

RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
RN624, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Anniston, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

NCT01129531
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
AGN-214868, Placebo to AGN-214868
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional

Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia

NCT00845923
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Patch
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
3
States / cities
Sunrise, Florida • Chicago, Illinois • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 4, 2026, 7:54 AM EDT
Not listed Phase 2 Interventional

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

NCT00813826
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
SLC022, Placebo
Drug
Lead sponsor
Solace Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Sierra Vista, Arizona • Mission Viejo, California • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 2 Interventional

Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)

NCT00609323
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
lidocaine and tetracaine cream 7%/7%, Placebo
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Lexington, Kentucky • High Point, North Carolina • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Oct 4, 2026, 7:54 AM EDT
Terminated Phase 2 Interventional Results available

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

NCT01886313
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Nasal Spray, Placebo
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Santa Monica, California • Lauderdale Lakes, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 4, 2026, 7:54 AM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 4, 2026, 7:54 AM EDT